Seres Therapeutics Inc. (NASDAQ:MCRB) has a beta value of 3.92 and has seen 1,269,048 shares traded in the last trading session. The company, currently valued at $1.97 Billion, closed the last trade at $21.48 per share which meant it gained $1.13 on the day or 5.55% during that session. The MCRB stock price is -79.24% off its 52-week high price of $38.5 and 85.66% above the 52-week low of $3.08. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.24 Million shares traded. The 3-month trading volume is 1.11 Million shares.
The consensus among analysts is that Seres Therapeutics Inc. (MCRB) is a Buy stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 9 have rated it as a Hold, with 7 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.31.
Seres Therapeutics Inc. (NASDAQ:MCRB) trade information
Sporting 5.55% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Apr 28 when the MCRB stock price touched $22.14- or saw a rise of 2.98%. Year-to-date, Seres Therapeutics Inc. shares have moved -12.33%, while the 5-day performance has seen it change 1.37%. Over the past 30 days, the shares of Seres Therapeutics Inc. (NASDAQ:MCRB) have changed 5.04%. Short interest in the company has seen 7.94 Million shares shorted with days to cover at 7.15.
Wall Street analysts have a consensus price target for the stock at $37.29, which means that the shares’ value could jump 73.6% from current levels. The projected low price target is $24 while the price target rests at a high of $47. In that case, then, we find that the current price level is +118.81% off the targeted high while a plunge would see the stock lose 11.73% from current levels.
Seres Therapeutics Inc. (MCRB) estimates and forecasts
Figures show that Seres Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -22.98% over the past 6 months, with this year growth rate of -21.43%, compared to 8.2% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are -10.7% and -25% for the next quarter. Revenue growth from the last financial year stood is estimated to be -27.4%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +13.7% over the past 5 years. Earnings growth for 2021 is a modest +10%.
Seres Therapeutics Inc. (NASDAQ:MCRB)’s Major holders
Insiders own 9.23% of the company shares, while shares held by institutions stand at 88.55% with a share float percentage of 97.55%. Investors are also buoyed by the number of investors in a company, with Seres Therapeutics Inc. having a total of 220 institutions that hold shares in the company. The top two institutional holders are Flagship Pioneering Inc. with over 14.67 Million shares worth more than $359.51 Million. As of December 30, 2020, Flagship Pioneering Inc. held 16.03% of shares outstanding.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The other major institutional holder is ARK Investment Management, LLC, with the holding of over 13.74 Million shares as of December 30, 2020. The firm’s total holdings are worth over $336.66 Million and represent 15.01% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Innovation ETF and Fidelity Growth Company Fund. As of March 30, 2021, the former fund manager holds about 7.69% shares in the company for having 7036818 shares of worth $144.89 Million while later fund manager owns 4.46 Million shares of worth $84.97 Million as of February 27, 2021, which makes it owner of about 4.87% of company’s outstanding stock.